Show simple item record

Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective

dc.contributor.authorSharma, Prateeken_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorHunt, Richarden_US
dc.contributor.authorLaine, Lorenen_US
dc.contributor.authorMalfertheiner, Peteren_US
dc.contributor.authorWani, Sachinen_US
dc.date.accessioned2010-06-01T18:31:45Z
dc.date.available2010-06-01T18:31:45Z
dc.date.issued2009-08en_US
dc.identifier.citationSharma, Prateek; Chey, William; Hunt, Richard; Laine, Loren; Malfertheiner, Peter; Wani, Sachin (2009). "Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective." Diseases of the Esophagus 22(5): 461-466. <http://hdl.handle.net/2027.42/71735>en_US
dc.identifier.issn1120-8694en_US
dc.identifier.issn1442-2050en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71735
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19191851&dopt=citationen_US
dc.description.abstractGastroesophageal reflux disease (GERD) is an extremely common chronic disorder associated with impaired quality of life and huge economic burden. Recently, an International Consensus Group developed a global definition of GERD (The Montreal Definition): a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The traditional endoscopy-based classification of GERD patients into one of three groups – non-erosive reflux disease, erosive esophagitis, and Barrett's esophagus – is fraught with several limitations. Due to the lack of a gold standard, GERD is a symptom-based diagnosis, and hence symptom evaluation will remain the primary means by which treatment decisions are made for patients with suspected GERD. We propose that patients reporting the predominant GERD-like symptoms (GERS) in the primary care setting be classified based upon their response to an empiric trial of acid suppressive therapy: complete response to acid suppressive therapy, partial response to acid suppressive therapy, and no response to acid suppressive therapy. Given the limitations of objective medical testing, implementation of our proposed new symptom-based classification of patients with GERS would guide primary care physicians on when to refer patients to a gastroenterologist, which in turn could help in better resource utilization. Validation of this proposed classification by well-designed prospective multicenter studies is awaited.en_US
dc.format.extent117854 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2009 International Society for Diseases of the Esophagusen_US
dc.subject.otherBarrett's Esophagusen_US
dc.subject.otherEndoscopyen_US
dc.subject.otherErosive Esophagitisen_US
dc.subject.otherGastroesophageal Reflux Diseaseen_US
dc.subject.otherNon-erosive Reflux Diseaseen_US
dc.titleEndoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspectiveen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan;en_US
dc.contributor.affiliationotherDivision of Gastroenterology and Hepatology, University of Kansas School of Medicine and Veterans Affairs Medical Center, Kansas City, Missouri;en_US
dc.contributor.affiliationotherDivision of Gastroenterology, McMaster University Medical Center, Hamilton, Ontario, Canada;en_US
dc.contributor.affiliationotherGI Liver Division, USC School of Medicine, Los Angeles, California, USA; anden_US
dc.contributor.affiliationotherOtto-von Guericke University of Magdeburg, Magdeburg, Germanyen_US
dc.identifier.pmid19191851en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71735/1/j.1442-2050.2008.00934.x.pdf
dc.identifier.doi10.1111/j.1442-2050.2008.00934.xen_US
dc.identifier.sourceDiseases of the Esophagusen_US
dc.identifier.citedreferenceBardhan K D, Stanghellini V, Armstrong D, BerghÖfer P, Gatz G, MÖnnikes H. Evaluation of GERD symptoms during therapy. Part I: development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 229 – 37.en_US
dc.identifier.citedreferenceKulig M, Nocon M, Vieth M et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the proGERD study. J Clin Epidemiol 2004; 57 ( 6 ): 580 – 9.en_US
dc.identifier.citedreferenceShaheen N J, Hansen R A, Morgan D R et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128 – 38.en_US
dc.identifier.citedreferenceLiu J Y, Woloshin S, Laycock W S, Rothstein R I, Finlayson S R, Schwartz L M. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med 2004; 164: 2058 – 64.en_US
dc.identifier.citedreferenceHeading R C. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999; 231: 3 – 8.en_US
dc.identifier.citedreferenceDent J, El-Serag H B, Wallander M A, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710 – 7.en_US
dc.identifier.citedreferenceTalley N J, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy negative heartburn: reliability and severity of disease-specific instruments. Am J Gastroenterol 2001; 96: 1998 – 2004.en_US
dc.identifier.citedreferenceMcDougall N I, Johnston B T, Kee F, Collins J S, McFarland R J, Love A H. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patients symptomatology and quality of life. Gut 1996; 38: 481 – 6.en_US
dc.identifier.citedreferenceDent J. Definitions of reflux disease and its separation from dyspepsia. Gut 2002; 50 ( Suppl 4 ): iv17 – 20.en_US
dc.identifier.citedreferenceDent J, Brun J, Fendrick A M et al. An evidence-based appraisal of reflux disease management–the Genval Workshop Report. Gut 1999; 44 ( Suppl 2 ): S1 – 16.en_US
dc.identifier.citedreferenceVakil N, van Zanten S V, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900 – 20.en_US
dc.identifier.citedreferenceFalk G W, Fennerty B F, Rothstein R I. AGA institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 2006; 131 ( 4 ): 1315 – 36.en_US
dc.identifier.citedreferenceLocke G R III, Talley N J, Fett S L, Zinsmeister A R, Melton L J III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112 ( 5 ): 1448 – 56.en_US
dc.identifier.citedreferenceFass R, Ofman J J. Gastroesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901 – 9.en_US
dc.identifier.citedreferenceKahrilas P J. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S15 – 23.en_US
dc.identifier.citedreferenceRonkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275 – 85.en_US
dc.identifier.citedreferenceCarlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease (GORD) in primary care–an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119 – 24.en_US
dc.identifier.citedreferenceQuigley E M. Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13 ( Suppl 1 ): S13 – 8.en_US
dc.identifier.citedreferenceQuigley E M. The spectrum of GERD: a new perspective. Drugs Today 2005; 41 ( Suppl B ): 3 – 6.en_US
dc.identifier.citedreferenceFass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005; 22: 79 – 94.en_US
dc.identifier.citedreferenceQuigley E M. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004; 18 ( 4 ): 695 – 706.en_US
dc.identifier.citedreferenceShaw M. Diagnostic utility of reflux disease symptoms. Gut 2004; 53 ( Suppl IV ): iv25 – 27.en_US
dc.identifier.citedreferenceMonnikes H, Bardhan K D, Stanghellini V, BerghÖfer P, Bethke T D, Armstrong D. Evaluation of GERD symptoms during therapy. Part II: psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69: 238 – 44.en_US
dc.identifier.citedreferenceVan Pinzteren B, Numans M, Bonis P, Lau J. Short-term treatment with proton pump inhibitors, H2 receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001: CD002095.en_US
dc.identifier.citedreference25  National Institute for Clinical Excellence. Dyspepsia: management of dyspepsia in adults in primary care. Clinical guideline 17, 2004 Aug. [Cited September 17, 2008] Available from URL: http://www.nice.org.uk/CG017NICEguidelineen_US
dc.identifier.citedreferenceVakil N. How valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2005; 22 ( Suppl 1 ): 64 – 9.en_US
dc.identifier.citedreferenceBardhan K D, Muller-Lissner S, Bigard M A et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 502 – 7.en_US
dc.identifier.citedreferenceLind T, Havelund T, Carlsson R et al. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974 – 9.en_US
dc.identifier.citedreferenceDean B B, Gano A D, Knight K, Ofman J J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656 – 64.en_US
dc.identifier.citedreferenceNumans M E, Lau J, de Wit N J, Bonis P A. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518 – 27.en_US
dc.identifier.citedreferenceNojkov B, Chey W D, Adlis S, Shaw M. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Gastroenterology 2005; 128: AB416.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.